COSCIENS Biopharma (CSCI) Competitors $3.13 +0.13 (+4.33%) Closing price 08/27/2025 03:55 PM EasternExtended Trading$3.13 0.00 (-0.13%) As of 08/27/2025 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock CSCI vs. KLTO, RNXT, BTAI, ESLA, EGRX, SCYX, CLSD, SNYR, AKTX, and MURAShould you be buying COSCIENS Biopharma stock or one of its competitors? The main competitors of COSCIENS Biopharma include Klotho Neurosciences (KLTO), RenovoRx (RNXT), BioXcel Therapeutics (BTAI), Estrella Immunopharma (ESLA), Eagle Pharmaceuticals (EGRX), SCYNEXIS (SCYX), Clearside Biomedical (CLSD), Synergy CHC (SNYR), Akari Therapeutics (AKTX), and Mural Oncology (MURA). These companies are all part of the "pharmaceutical products" industry. COSCIENS Biopharma vs. Its Competitors Klotho Neurosciences RenovoRx BioXcel Therapeutics Estrella Immunopharma Eagle Pharmaceuticals SCYNEXIS Clearside Biomedical Synergy CHC Akari Therapeutics Mural Oncology COSCIENS Biopharma (NASDAQ:CSCI) and Klotho Neurosciences (NASDAQ:KLTO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings. Which has more volatility and risk, CSCI or KLTO? COSCIENS Biopharma has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Klotho Neurosciences has a beta of 10.9, suggesting that its stock price is 990% more volatile than the S&P 500. Does the media prefer CSCI or KLTO? In the previous week, COSCIENS Biopharma and COSCIENS Biopharma both had 1 articles in the media. COSCIENS Biopharma's average media sentiment score of 1.88 beat Klotho Neurosciences' score of 1.87 indicating that COSCIENS Biopharma is being referred to more favorably in the media. Company Overall Sentiment COSCIENS Biopharma Very Positive Klotho Neurosciences Very Positive Which has preferable valuation & earnings, CSCI or KLTO? Klotho Neurosciences has lower revenue, but higher earnings than COSCIENS Biopharma. Klotho Neurosciences is trading at a lower price-to-earnings ratio than COSCIENS Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCOSCIENS Biopharma$9.59M1.03-$15.31M-$6.01-0.52Klotho NeurosciencesN/AN/A-$6.15M-$0.45-1.62 Do insiders & institutionals believe in CSCI or KLTO? 0.7% of COSCIENS Biopharma shares are owned by institutional investors. Comparatively, 20.1% of Klotho Neurosciences shares are owned by institutional investors. 0.1% of COSCIENS Biopharma shares are owned by company insiders. Comparatively, 26.7% of Klotho Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is CSCI or KLTO more profitable? Klotho Neurosciences has a net margin of 0.00% compared to COSCIENS Biopharma's net margin of -199.55%. COSCIENS Biopharma's return on equity of -149.49% beat Klotho Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets COSCIENS Biopharma-199.55% -149.49% -54.80% Klotho Neurosciences N/A -325.88%-242.15% SummaryKlotho Neurosciences beats COSCIENS Biopharma on 6 of the 11 factors compared between the two stocks. Get COSCIENS Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CSCI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CSCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CSCI vs. The Competition Export to ExcelMetricCOSCIENS BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.44M$3.10B$5.76B$9.78BDividend YieldN/A2.26%3.95%4.03%P/E Ratio-0.5221.0830.8026.37Price / Sales1.03396.73467.21121.82Price / CashN/A44.4437.7659.36Price / Book1.388.0610.106.62Net Income-$15.31M-$54.08M$3.26B$265.42M7 Day Performance18.83%2.51%2.85%3.15%1 Month Performance-17.85%3.55%4.01%0.82%1 Year Performance-17.41%18.40%42.88%22.99% COSCIENS Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CSCICOSCIENS BiopharmaN/A$3.13+4.3%N/AN/A$9.44M$9.59M-0.5220Positive NewsGap UpHigh Trading VolumeKLTOKlotho NeurosciencesN/A$0.78-0.2%N/AN/A$36.21MN/A-1.74N/APositive NewsRNXTRenovoRx3.0335 of 5 stars$0.92-2.0%$7.25+686.8%-3.7%$34.38M$40K-2.426Analyst ForecastBTAIBioXcel Therapeutics4.567 of 5 stars$4.92-13.2%$39.75+707.9%-62.4%$34.34M$2.27M-0.3990Trending NewsGap DownESLAEstrella Immunopharma3.1357 of 5 stars$0.92+0.1%$16.00+1,639.1%-15.3%$34.08MN/A-3.54N/AGap UpEGRXEagle PharmaceuticalsN/A$2.60-18.8%N/A-33.0%$33.77M$257.55M0.00100SCYXSCYNEXIS1.1286 of 5 stars$0.79-1.6%N/A-43.6%$33.65M$3.75M-1.9760CLSDClearside Biomedical2.6647 of 5 stars$0.40-5.6%$4.20+944.8%-61.7%$33.44M$1.66M-1.0930Positive NewsSNYRSynergy CHC4.3798 of 5 stars$3.28-5.7%$10.00+204.9%N/A$32.86M$34.83M8.6340AKTXAkari Therapeutics3.0421 of 5 stars$0.99-0.9%$5.00+404.3%-77.4%$32.18MN/A0.009Positive NewsMURAMural Oncology2.7321 of 5 stars$1.80-1.1%$12.00+566.7%-37.4%$31.53MN/A-0.21119 Related Companies and Tools Related Companies KLTO Competitors RNXT Competitors BTAI Competitors ESLA Competitors EGRX Competitors SCYX Competitors CLSD Competitors SNYR Competitors AKTX Competitors MURA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CSCI) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COSCIENS Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share COSCIENS Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access